AbbVie | ABBV - Operating Expenses

Stock Price
225.64
Daily Change
2.63 1.18%
Monthly
2.48%
Yearly
18.67%
Q1 Forecast
216.14

AbbVie reported $-2.64B in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD -2.64B 12.35B Sep/2025
Abbott USD 9.21B 17M Dec/2025
ALKERMES USD 1.73B 1.44B Sep/2025
Amgen USD 5.13B 1.39B Sep/2025
AstraZeneca USD 16.69B 5.74B Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Bristol-Myers Squibb USD 18.55B 10.06B Sep/2025
Eisai JPY 183.69B 1.78B Sep/2025
Eli Lilly USD 9.21B 677.8M Sep/2025
Gilead Sciences USD 4.26B 95M Sep/2025
GlaxoSmithKline GBP 5.76B 203M Sep/2025
J&J USD 18.97B 2.38B Dec/2025
Medtronic USD 7.26B 283M Sep/2025
Merck USD 10.72B 1.28B Sep/2025
Neurocrine Biosciences USD 555.6M 13.7M Sep/2025
Novartis USD 9.86B 115M Sep/2025
Pacira USD 166.36M 4.5M Sep/2025
Perrigo USD 949.9M 50.8M Sep/2025
Pfizer USD 92.8B 82.47B Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
UCB EUR 2.36B 108M Dec/2024
Ultragenyx Pharmaceutical USD 330.82M 56.44M Sep/2025
United Therapeutics USD 6.59B 6.07B Sep/2025
Vertex Pharmaceuticals USD 1.84B 27.1M Sep/2025
Zoetis USD 5.4B 3.94B Sep/2025